Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has ...

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR ...

The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

The study reveals that excessive activation of mTOR contributes to kidney injury by inhibiting autophagy, increasing oxidative stress, and promoting inflammation. It examines the impact of mTOR on ...

In particular, the mechanistic target of rapamycin (mTOR) pathway has been tied to multiple age-related chronic disease processes, such as declining immune function, diminishing bone mineral ...

It activates the mTOR pathway, which is crucial for cellular growth and repair. Additionally, leucine is beneficial for aging individuals as it helps prevent muscle loss (sarcopenia) and supports ...

The authors discuss several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and the DNA damage response (DDR). These ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...